Benredjem, Besma
Gallion, Jonathan
Pelletier, Dennis
Dallaire, Paul
Charbonneau, Johanie
Cawkill, Darren
Nagi, Karim http://orcid.org/0000-0002-4700-5568
Gosink, Mark
Lukasheva, Viktoryia
Jenkinson, Stephen
Ren, Yong
Somps, Christopher
Murat, Brigitte
Van Der Westhuizen, Emma http://orcid.org/0000-0001-9165-8526
Le Gouill, Christian
Lichtarge, Olivier
Schmidt, Anne
Bouvier, Michel http://orcid.org/0000-0003-1128-0100
Pineyro, Graciela
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé
Mitacs
Gouvernement du Canada | Canadian Institutes of Health Research (102630, MOP 102630, 324876)
Foundation for the National Institutes of Health (2R01 GM066099, 5R01 GM079656)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (311997)
Pfizer
Article History
Received: 22 June 2018
Accepted: 6 August 2019
First Online: 9 September 2019
Change Date: 16 April 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: M.B., C.L., and G.P. have a patent on BRET biosensors licensed to Domain Therapeutics North America and Pfizer Inc. The remaining authors declare no competing interests.